Navigation Links
Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer

his year. Data presented at previous AACR meetings highlighted the antitumor effects of ABT-869 across a broad range of tumor models.

Other Compounds

Abbott scientists remain dedicated to exploring a variety of cutting-edge treatments in the fight against cancer. In addition to Bcl-2 family protein inhibitors, PARP inhibitors and kinase inhibitors, other compounds moving through the development pipeline include ABT-751, an oral, once-daily antimitotic (a class of drugs that inhibit cell division) in ongoing studies for non-small cell lung cancer, and ABT-828, a biologic compound that blocks angiogenesis of cancer cells.

About Abbott Oncology

Abbott Oncology is committed to the discovery and development of innovative cancer treatments that enable patients to live longer and healthier lives. Abbott's oncology research is focused on developing more targeted, less toxic therapies than are currently available to improve the quality of life for some patients living with cancer.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

CONTACT: media, Catherine Bryan, +1-847-936-6722, financial, Tina Ventura,+1-847-935-9390, both of Abbott

Web site: http://www.abbott.com/

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. NIEHS Researchers Identify Enzyme Critical in DNA Replication
11. Stanford Researchers Find Brain Pathway of Depression in Rats
Post Your Comments:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Corporation (NASDAQ: HSKA ), a provider of ... today announced that Robert Grieve, Heska,s Chairman and CEO, will ... (PT), on March 14, 2012, Salon 1, Burgandy Track.  The ... Carlton, 1 Ritz Carlton Drive, Dana Point, California.  Dr. Grieve ...
... BETHESDA, Md., Feb. 23, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) ... clinical trial sites open and recruiting across the United ... DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most ... milestone ahead of schedule, as the Company had projected ...
Cached Medicine Technology:Heska to Present at the 24th Annual ROTH Conference 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 3
(Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Weight loss improves the sexual health of obese men with ... placed 31 obese men with type 2 diabetes on either ... diet meant to decrease calorie intake by 600 calories a ... to an easing of erectile dysfunction and improved sexual desire ...
... People living in a region of the southeastern United States ... higher rates of stroke deaths than the rest of the ... risk for sepsis, a severe illness in which bacteria overwhelms ... sepsis across the United States," said Dr. Henry Wang, associate ...
... University of Massachusetts Medical School have uncovered a novel ... immune response for malaria. Activation of this pathway appears ... by the immune system that may contribute to inflammation ... part in susceptibility for the most common and lethal ...
... , THURSDAY, Aug. 4 (HealthDay News) -- A ... comfortable using the clot-busting drug tissue plasminogen activator (tPA) to ... finds. An ischemic stroke is caused by blocked blood ... of neurology residents who say they,re comfortable using tPA rose ...
... have completed a comprehensive map of genetic mutations occurring ... The findings, reported in the Aug. 4 issue ... biological cause of the tumors, they say. To ... seven oligodendroglioma tissue samples, and focused attention on recurring ...
... the United States spend nearly four times as much dealing ... Most of the difference stems from the fact that Canadian ... multiple payers in the United States. These findings are ... -- the result of a research collaboration among Weill Cornell ...
Cached Medicine News:Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 3Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3
Cholesterol/HDL with 200 tests....
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
Medicine Products: